Neurofenix

Neurofenix operates at the intersection of digital therapeutics, virtual care, remote patient monitoring, and medical devices, with a specific focus on stroke and neurological rehabilitation. Its offering combines therapist-led virtual programs, a portable NeuroBall device, gamified high-repetition exercises, remote usage data, and clinician-facing progress reporting. That integrated model differentiates it from standalone telehealth providers that do not supply rehabilitation hardware, and from device companies that lack an ongoing virtual-care layer. The company’s Florida virtual clinic, launched on Jun 6, 2024, suggests a move beyond a UK-only service model toward geographically distributed care delivery. The reported categories include generic and apparently inconsistent labels such as Automotive and Autonomous Vehicles, while the company’s products and positioning clearly center on healthcare. Its $6.92 million disclosed funding total and 11–50 employee range indicate a focused growth-stage operation rather than a scaled incumbent. Medicare-covered therapy and same-day enrollment may strengthen access, but geographic coverage and payer expansion remain unclear.

Neurofenix was founded in 2016 and has progressed from early seed financing to a substantial Series A. The company raised $13,304 in a 2016 seed round, recorded additional seed and grant activity in May 2017 and a further seed round on Feb 15, 2020, then announced a £5.9 million Series A on Aug 29, 2022. AlbionVC led that round, with InHealth Ventures and HTH also participating, bringing reported total funding to $6.92 million. The financing appears to have supported a shift from a device-centered rehabilitation concept toward a broader virtual-care platform combining NeuroBall, home rehabilitation kits, therapist support, remote monitoring, and clinical dashboards. The Jun 6, 2024 Florida virtual-clinic launch is the strongest visible expansion inflection point, demonstrating an effort to deliver home-based neurorehabilitation in a new market. The 2023 CareCloud selection points to operational scaling needs as service delivery expanded. No later financing, revenue, or employee-growth milestones are disclosed.